| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/13543770802608048 |
| P698 | PubMed publication ID | 19441895 |
| P2093 | author name string | A K Saha | |
| D D'Cruz | |||
| P2860 | cites work | The L-arginine-nitric oxide pathway | Q24304874 |
| Thrombosis, abortion, cerebral disease, and the lupus anticoagulant | Q24675412 | ||
| Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals | Q28217805 | ||
| Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial | Q28217835 | ||
| Role of tissue factor in hemostasis, thrombosis, and vascular development | Q28259220 | ||
| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) | Q28292418 | ||
| Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors | Q28294390 | ||
| Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects | Q28319507 | ||
| Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor | Q28565242 | ||
| Platelets possess and require an active protein palmitoylation pathway for agonist-mediated activation and in vivo thrombus formation | Q33274055 | ||
| Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients | Q33341941 | ||
| Molecular pathogenesis of the antiphospholipid syndrome | Q34489999 | ||
| Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial | Q34754096 | ||
| Mechanisms of thrombus formation | Q34815800 | ||
| Boronic acid compounds as potential pharmaceutical agents | Q35088857 | ||
| Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury | Q36007691 | ||
| P-selectin glycoprotein ligand-1 VNTR polymorphisms and risk of thrombosis in the antiphospholipid syndrome | Q36013889 | ||
| Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model | Q36300619 | ||
| New targeted therapies for treatment of thrombosis in antiphospholipid syndrome | Q36998932 | ||
| Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. | Q37035823 | ||
| Dietary and viscosupplementation in ankle arthritis | Q37240321 | ||
| A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial | Q39435913 | ||
| A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. | Q40456744 | ||
| Antithrombin and its inherited deficiencies | Q40763239 | ||
| Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK) | Q43810060 | ||
| Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism | Q44659783 | ||
| Ximelagatran--promises and concerns | Q45258342 | ||
| Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis | Q48394757 | ||
| The Protein C Pathway | Q56502503 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 13-22 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | Expert Opinion on Therapeutic Patents | Q5421213 |
| P1476 | title | New potential therapies for the treatment of antiphospholipid syndrome | |
| P478 | volume | 19 |
| Q38251303 | Prolinamide derivatives as thrombin inhibitors for the treatment of thrombin-mediated diseases: a patent evaluation of US2013296245. | cites work | P2860 |
Search more.